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We had previously reported that the administration of bone marrow mesenchymal stromal cells (MSCs) therapy to two patients with mild AD dementia, led to a global increase in cerebral glucose metabolism,
which was accompanied by significant improvement of visual short-term memory binding (VSTMB), a function known to be a marker of AD (Fernández-Guinea et al., 2019). We suggested that intrathecal
administration of MSCs could be considered a new therapeutic strategy for AD dementia (Vaquero et al., 2019). We were interested in investigating the post-intervention durability of such cognitive improvements.
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Results
VSTMB Test: It requires subjects to detect whether or not two combinations of shape and 
colour change across  two sequential arrays.
Changes in 18F-FDG-PET in case 1 and case 2 from Vaquero et al, 2019.
Impact of Intrathecal Cell Therapy with Autologous Stromal Cells on Short-Term Memory Binding in Early 
Alzheimer’s Disease: One-Year Follow-up Assessment
This task has been proposed as a 
preclinical marker of AD (Dubois et al 2016).
Case 1. A-C: beta-amyloid neuritic plaques with 18F-Flutemetamol-PET.
D-E: 18F-FDG-PET previous to cell therapy and one week after first 
intrathecal administration of 100 millions MSCs (G-I).
Case 2. 18F-FDG-PET showing metabolic activity previous to 
cell therapy (A-C) and at the end of treatment (D-F).
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Clinical procedures and experimental task:
Intrathecal cell therapy with autologous MSCs increases cerebral glucose metabolism, being associated with neuropsychological improvements in patients experiencing early stages of AD. Improvements
of memory functions known to be marker for AD in patients who underwent stem cell therapy remained stable after one year post-intervention. This type of cell therapy is safe, allowing distribution of
donor cells in the whole brain. Administration of autologous MSCs should be considered as a new therapeutic strategy for Alzheimer’s dementia and deserves further studies.
Conclusions
STMB TASK PRE POST 1 POST 2 POST 3 (END) POST 4 (+1YR)
Shape Only 100% 100% 94% 100% 100%
Shape-Colour Binding 50% 62% 66% 62% 67%
STMB TASK PRE POST 1 POST 2 POST 3 (END) POST 4 (+1YR)
Shape Only 88% 91% 88% 88% 91%
Shape-Colour Binding 52% 69% 66% 81% 44%
Single case statistics revealed that benefits drawn by treated patients from the therapy remained a year after. Using a more taxing version of the VSTMB test (memory load of 3 items) we observed that, after the therapy, the chance that an untreated AD patient
would show more impairment was 75.45% (p= 0.24) for Case 1 and 89.23% (p=0.11) for case 2. This chance remained after 1 year post-treatment for Case 1 (75.45%, p=0.24) and increased for Case 2 (96.89%, p=0.031).
2 patients received every three months 100 million of autologous MSCs by intrathecal route, until a total dose of 300 million. None received any other medication for its disease at the time of receiving cell therapy.
N=6 Diagnosis of Alzheimer’s disease. 2 of them received cellular therapy. 
Without medication
Detection of beta-amyloid neuritic plaques  (18F-Flutemetamol-PET).
Brain glucose metabolism studied with 18F-FDG-PET
.
Participants: Neuropsychological assessment:
MMSE                                                          Rey Complex Figure Test 
Addenbrooke’s Cognitive Examination Stroop Test
Barthel ADL Scale TAVEC (Spanish CVLT)
Lawton and Brody IADL                                WAIS-IV
Clinical Dementia Rating Scale
Rey Complex Figure Test
